60 DEGREES PHARMACEUTICALS LLC (SXTP)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.92-4.17%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · SXTP
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Favorable clinical and conventional-PCR outcomes in all five completed patients and an 80% post-treatment NAT-negative rate provide molecular evidence consistent with definitive cure in four of five…
Stated in a supplied disclosure. Management reported: “Favorable clinical and conventional-PCR outcomes in all five completed patients and an 80% post-treatment NAT-negative rate provide molecular evidence consistent with definitive cure in four of five patients.” “30 Hospital subjects randomized Blinded follow-up completes in early January 2027; unblinding follows.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
CHRONIC DIAGNOSTICS RELAPSING DISEASE HOSPITAL READOUT Regulatory objective A potential sNDA in 2027, and a request for national-priority review.
Stated in a supplied disclosure. Management reported: “CHRONIC DIAGNOSTICS RELAPSING DISEASE HOSPITAL READOUT Regulatory objective A potential sNDA in 2027, and a request for national-priority review.” “Following unblinding, the Company intends to request a pre-supplemental New Drug Application (pre-sNDA) meeting with FDA to discuss data from the hospital and expanded access studies and the appropriate regulatory pathway for tafenoquine in babesiosis.”
2 The Company expects to unblind its separate randomized, placebo-controlled study of tafenoquine or placebo added to standard-of-care therapy in patients hospitalized for babesiosis (NCT06207370) in…
Stated in a supplied disclosure. Management reported: “30 Hospital subjects randomized Blinded follow-up completes in early January 2027; unblinding follows.” “2 The Company expects to unblind its separate randomized, placebo-controlled study of tafenoquine or placebo added to standard-of-care therapy in patients hospitalized for babesiosis (NCT06207370) in January 2027.”
Management ties the 2028 profitability objective to continued malaria-prevention commercial growth and a babesiosis supplemental indication.
Achieve profitability by 2028 through continued commercial growth in malaria prevention and obtaining supplemental indication for babesiosis.
Over the trailing year it converted 1.00x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
18 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-05.